Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can CBD calm social anxiety? MIT study seeks answers

NCT ID NCT05649059

Symptom relief Sponsor: Massachusetts Institute of Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tests whether a single dose of the drug Epidiolex (cannabidiol, or CBD) can reduce feelings of anxiety, physical stress signs, and brain activity linked to anxiety in people with social anxiety disorder. About 50 adults aged 18-55 with significant social anxiety will take part. Researchers will measure anxiety before and after a stressful public speaking task.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability and willingness to provide written informed consent. * Sufficiently fluent in English to participate in the trial. * Between 18-55 years of age (inclusive). * Right-hand dominant. * Current medications are stable for past 30 days (no changes to dose or frequency). * Negative result on pregnancy test (if female). * Negative result on urine drug screening. * Liebowitz Social Anxiety Scale (LSAS ≥ 60). Exclusion Criteria: * History of bipolar disorder, schizophrenia, psychosis, delusional disorders. * History of eating disorder within past 6 months. * History of any traumatic brain injury. * Currently diagnosed with diabetes mellitus. * Presence of severe medical illness that would prevent completion of study procedures. * Presence of significant neurological illness or cognitive dysfunction (e.g.; seizures, dementia). * History of substance use disorder within past 6 months (other than nicotine and caffeine). * Use of any cannabis-containing products in past 30 days (CBD or THC). * Use of benzodiazepines in past 2 weeks. * Use of alpha- or beta-blockers in past week. * History of claustrophobia. * Contraindications for MRI (e.g.; shrapnel). * Presence of any other medical condition that, in the investigator's opinion, may interfere with the study procedures. * Use of concomitant medication that has a strong interaction with CBD. * History of liver disease. * History of hypersensitivity to cannabinoids. * History of hypersensitivity to sesame seed oil. * Currently breastfeeding (if female).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Phobia, social are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

social phobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Phobia, social

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Massachusetts Institute of Technology

    RECRUITING

    Cambridge, Massachusetts, 02139, United States